Back to Search
ARIA OLUMI, MD FACS
MD FACS
Urology Physician
NPI: 1558315184IndividualAccepts Medicare
Specialties, Licenses & Credentials
Urology PhysicianPrimary
Urology
Code: 208800000X
78293(MA)
CMS Specialties
PrimaryUROLOGY
Education
UNIVERSITY OF SOUTHERN CALIFORNIA KECK SCHOOL OF MEDICINE
Class of 1992
Research & Publications (20)
Self-retraction clamp for dissection of the posterior prostatic fossa during radical retropubic prostatectomy.
PMID 15349550·ScientificWorldJournal·2004
8-other
Calculated volume of prostate cancer identifies patients with clinical stage T1C disease at high risk of biochemical recurrence after radical prostatectomy: a preliminary study.
PMID 10925093·Urology·2000
8-other
A critical analysis of the use of p53 as a marker for management of bladder cancer.
PMID 10696247·Urol Clin North Am·2000
6-review
Involvement of FLIP in 2-methoxyestradiol-induced tumor regression in transgenic adenocarcinoma of mouse prostate model.
PMID 19223508·Clin Cancer Res·2009
7-preclinical
Repression of NF-kappaB and activation of AP-1 enhance apoptosis in prostate cancer cells.
PMID 19123467·Int J Cancer·2009
8-other
Overcoming resistance to trail-induced apoptosis in prostate cancer by regulation of c-FLIP.
PMID 18603132·Methods Enzymol·2008
7-preclinical
Low-dose 12-O-tetradecanoylphorbol-13-acetate enhances tumor necrosis factor related apoptosis-inducing ligand induced apoptosis in prostate cancer cells.
PMID 18056199·Clin Cancer Res·2007
7-preclinical
pVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-kappaB agonist Card9 by CK2.
PMID 17936701·Mol Cell·2007
7-preclinical
c-Fos as a proapoptotic agent in TRAIL-induced apoptosis in prostate cancer cells.
PMID 17909052·Cancer Res·2007
7-preclinical
Novel targeted pro-apoptotic agents for the treatment of prostate cancer.
PMID 17868738·J Urol·2007
6-review
Stromally expressed c-Jun regulates proliferation of prostate epithelial cells.
PMID 17702894·Am J Pathol·2007
8-other
Hypoxia-inducible factor linked to differential kidney cancer risk seen with type 2A and type 2B VHL mutations.
PMID 17526729·Mol Cell Biol·2007
7-preclinical
MG-132 sensitizes TRAIL-resistant prostate cancer cells by activating c-Fos/c-Jun heterodimers and repressing c-FLIP(L).
PMID 17332355·Cancer Res·2007
8-other
Lexatumumab (TRAIL-receptor 2 mAb) induces expression of DR5 and promotes apoptosis in primary and metastatic renal cell carcinoma in a mouse orthotopic model.
PMID 17184908·Cancer Lett·2007
7-preclinical
Low age adjusted free testosterone levels correlate with poorly differentiated prostate cancer.
PMID 16515994·J Urol·2006
8-other
Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in prostate cancer.
PMID 15466204·Cancer Res·2004
8-other
Expression of transforming growth factor-beta 1 and growth in soft agar differentiate prostate carcinoma-associated fibroblasts from normal prostate fibroblasts.
PMID 15352032·Int J Cancer·2004
4-observational
Pathologic quiz case. A symptomatic renal tumor. Juxtaglomerular cell tumor.
PMID 15335262·Arch Pathol Lab Med·2004
5-case
Percent of cores positive for cancer is a better preoperative predictor of cancer recurrence after radical prostatectomy than prostate specific antigen.
PMID 15017206·J Urol·2004
4-observational
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 55 FRUIT STREET, MASSACHUSETTS GENERAL HOSPITAL YAWKEY CENTER SUITE 7E
BOSTON, MA 02114 - Phone
- (617) 643-0237
Quick Facts
- NPI
- 1558315184
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 34
- Publications
- 20
Are you this provider?
Claim Your Profile